Barclays reiterates its Overweight rating on pharmaceutical company Roche and describes the updates from the company’s drug day as positive, albeit not groundbreaking. This is according to an analysis.
Roche now sees up to 20 new drug compounds with launch potential by 2030, compared with 18 previously, and plans five new Phase 3 studies.
Barclays also highlights promising data for the obesity drug enicepatide. Positive pipeline updates are partly offset by delays affecting, among others, giredestrant and pegozafermin.
The unchanged financial targets are also in line with Barclays’ previous expectations.
